Synmosa Biopharma Corporation (TPEX:4114)

Market Cap	16.06B +12.8%
Revenue (ttm)	6.19B +11.5%
Net Income	821.85M +20.0%
EPS	1.66 +12.2%
Shares Out	502.77M
PE Ratio	19.25
Forward PE	n/a
Dividend	0.55 (1.71%)
Ex-Dividend Date	Jul 11, 2025

Volume	318,341
Average Volume	711,804
Open	32.00
Previous Close	31.95
Day's Range	31.70 - 32.00
52-Week Range	27.64 - 39.80
Beta	0.02
RSI	59.25
Earnings Date	Aug 28, 2026

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, engages in the manufacturing and sales of various pharmaceuticals and medical devices in Taiwan, China, the United States, Canada, Thailand, Malaysia, Singapore, and internationally. It offers medicines for urology, hormones, oncology, dermatology, cardiovascular, CNS, gastrointestinal, and other areas; and effervescent tables, granules, and nasal sprays. The company is also involved in provision of cosmetics, veterinary drugs, chemical food additives, and beverages; wholesale r...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1959
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4114

Financial Performance

In 2025, Synmosa Biopharma's revenue was 6.19 billion, an increase of 11.53% compared to the previous year's 5.55 billion. Earnings were 821.85 million, an increase of 20.03%.